Clinical kinetics of 1,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino]ethyl] amino]9,10-anthracenedione

Niramol Savaraj, Katherine Lu, Manuel Valdivieso, Michael Burgess, Theera Umsawasdi, Robert S. Benjamin, Ti Li Loo

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

The clinical kinetics of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthra cenedione dihydrochloride (DHAQ) are reported. DHAQ, 1 to 3 mg/m2, was administered as an intravenous bolus to six patients with metastatic cancer. Plasma clearance of the drug followed a biphasic pattern with a harmonic mean initial half-life (t 1 2) of 13.7 min and a terminal t 1 2 of 37.4 hr. Recovery of unchanged drug in the urine was 6.8% at 24 hr and 7.3% at 72 hr, while the corresponding recovery of total radioactivity was 9.4% and 11.3%. Apparent volume of distribution of DHAQ was about 13.8 ± 2.9 11kg. Total clearance was 238.7 ml/kg/hr, twice the creatinine clearance.

Original languageEnglish (US)
Pages (from-to)312-316
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume31
Issue number3
DOIs
StatePublished - Mar 1982
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical kinetics of 1,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino]ethyl] amino]9,10-anthracenedione'. Together they form a unique fingerprint.

  • Cite this